Protagonist Therapeutics, Inc. (PTGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Protagonist Therapeutics, Inc. on October 30, 2023, covering events occurring on October 26, 2023. The filing addresses corporate governance changes specifically regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its size from six to seven members.
- New Appointment: Daniel N. Swisher, Jr. was appointed as a Class I director, serving until the 2026 Annual Meeting of Stockholders.
- Compensation Arrangements:
- Annual cash compensation: $40,000.
- Equity grant: Option to purchase 45,000 shares of common stock.
- Exercise price: $14.21 per share (closing price on grant date).
- Vesting schedule: 36 equal monthly installments contingent on continued service.
Management Commentary and Risks
Mr. Swisher brings significant biopharmaceutical experience, having previously served as President and Chief Operating Officer of Jazz Pharmaceuticals plc and CEO of Sunesis Pharmaceuticals, Inc. He currently serves as a Strategic Advisor to Jazz Pharmaceuticals and sits on the boards of Cerus Corporation and Corcept Therapeutics Incorporated. The filing states there are no family relationships with existing directors or officers and no undisclosed material interests in transactions.
Key Facts for Investor Verification
- Verify the impact of the new board member on strategic direction given his background in commercialization and operations.
- Confirm the dilution impact of the 45,000 share option grant relative to total outstanding shares.
- Review the company's cash position to ensure it can sustain operations while adding director compensation costs.
- Check for any subsequent filings regarding the vesting status or exercise of the granted options.